Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
PLoS One. 2013 Jul 23;8(7):e70519. doi: 10.1371/journal.pone.0070519. Print 2013.
Serum markers represent potential tools for the detection of colorectal cancer (CRC). The aim of this study was to obtain proteomic expression profiles and identify serum markers for the early detection of CRC.
Proteomic profiles of serum samples collected from 35 healthy volunteers, 35 patients with advanced colorectal adenoma (ACA), and 40 patients with CRC were compared using Clinprot technology. Using enzyme-linked immunosorbent assays (ELISAs), 366 sera samples were additionally analyzed, and immunohistochemistry studies of 400 tissues were used to verify the expression of kininogen-1 and its value in the early detection of CRC.
Predicting models were established among the three groups, and kininogen-1 was identified as a potential marker for CRC using Clinprot technology. ELISAs also detected significantly higher serum kininogen-1 levels in ACA and CRC patients compared to controls (P<0.05). Furthermore, the area under the receiver operating characteristic curve (AUC) for serum kininogen-1 in the diagnosis of ACA was 0.635 (P=0.003), and for serum carcinoembryonic antigen (CEA) was 0.453 (P=0.358). The sensitivity, specificity, and accuracy of serum kininogen-1 for diagnosing Duke's stage A and B CRC was 70.13%, 65.88%, and 67.90%, respectively, whereas serum CEA was 38.96%, 85.88%, and 63.58%, respectively. Moreover, immunohistochemistry showed that expression of kininogen-1 was significantly higher in CRC and ACA tissues than in normal mucosa (48.39% vs. 15.58% vs. 0%, P<0.05).
These results suggest that Clinprot technology provides a useful tool for the diagnosis of CRC, and kininogen-1 is a potential serum biomarker for the early detection of advanced colorectal adenoma and CRC.
血清标志物代表用于结直肠癌（CRC）检测的潜在工具。本研究旨在获得蛋白质组表达谱并确定用于 CRC 早期检测的血清标志物。
使用 Clinprot 技术比较了来自 35 名健康志愿者、35 名晚期结直肠腺瘤（ACA）患者和 40 名 CRC 患者的血清样本的蛋白质组图谱。使用酶联免疫吸附测定法（ELISA）进一步分析了 366 份血清样本，并通过免疫组织化学研究验证了激肽原-1 的表达及其在 CRC 早期检测中的价值。
在这三组之间建立了预测模型，并使用 Clinprot 技术确定激肽原-1 是 CRC 的潜在标志物。ELISA 还检测到 ACA 和 CRC 患者的血清激肽原-1 水平明显高于对照组（P<0.05）。此外，血清激肽原-1 对 ACA 的诊断的受试者工作特征曲线（ROC）下面积（AUC）为 0.635（P=0.003），而血清癌胚抗原（CEA）为 0.453（P=0.358）。血清激肽原-1 诊断 Duke's A 期和 B 期 CRC 的敏感性、特异性和准确性分别为 70.13%、65.88%和 67.90%，而血清 CEA 分别为 38.96%、85.88%和 63.58%。此外，免疫组化显示，CRC 和 ACA 组织中激肽原-1 的表达明显高于正常黏膜（48.39%比 15.58%比 0%，P<0.05）。
这些结果表明 Clinprot 技术为 CRC 的诊断提供了一种有用的工具，激肽原-1 是早期检测晚期结直肠腺瘤和 CRC 的潜在血清生物标志物。
